Our first product is a universal complement SARS coronavirus vaccine candidate. The antigen is designed to elicit a new class of antibodies neutralizing all new variants. The antigen is displayed on a self-assembling nanoparticle directly encoded by messenger RNAs. This nanoparticle enhances immune response, including long term adaptive cell-mediated immunity. The pursued advantages of our nanoparticle vaccine are longer protection, protection against viral dissemination and associated neuropathology, and reduction of the number of challenges necessary for immunization.

Parallel Tracks

Phylex BioSciences follows parallel tracks for preclinical-grade manufacturing and cGMP manufacturing of our candidate vaccines. This will allow the company to move directly into cGMP production after our preclinical immunogenicity and protection studies are completed.

Phylex BioSciences follows parallel tracks for the formulation and delivery of our mRNA candidate vaccine. The immunogenicity results of different formulations of our mRNA encoding our nanoparticle are obtained at the same time.

Phylex BioSciences is pursuing a mRNA formulation with the objective of eliminating cold chain logistics for our candidate mRNA vaccine.